Oncomed Pharmaceuticals Inc., of Redwood City, Calif., enrolled the first biomarker-selected patient in its anti-Notch1 antibody phase Ia solid tumor clinical trial, triggering a $5 million milestone payment from partner Glaxosmithkline plc, of London.